Project Grant R01AI198150
Award Date 8/21/26
Completion Date 7/31/31
Dollars Obligated $889K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $707,928 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on epitope-engineered hematopoietic stem cells to enable CAR-T cell-mediated CD4 depletion as an HIV cure strategy. The project integrates genome editing with targeted cellular immunotherapy to establish an HIV-refractory immune system while eliminating persistent HIV-infected...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $162,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the single-cell epigenetic landscape of the HIV-1 reservoir for effective latency reversal. The research will characterize proviral epigenetics—the regulation of transcription at the chromatin level independent of DNA sequence—to understand how latent HIV is established,...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $506,550 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI200714). The award funds research to improve HIV-specific CAR T cell therapy by neutralizing persistent Type-I Interferon signaling. The project will identify mechanisms by which chronic interferon-beta exposure mediates HIV-specific CAR T cell dysfunction and...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $888,042 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate N332-glycan-independent V3-glycan antibodies as targets for HIV-1 vaccine design. The research develops novel broadly neutralizing antibody responses against HIV-1 envelope protein by studying vaccine candidates that elicit antibodies binding to the V3-glycan epitope...
- The National Institute of Allergy and Infectious Diseases awarded George Washington University $781,999 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decipher mechanisms regulating the HLA-F and KIR3DS1 interaction in natural killer cells and HIV pathogenesis. The project, titled "Deciphering the Role of HLA-F and KIR3DS1 on NK Function and HIV Pathogenesis," focuses on understanding how the interaction between the KIR3DS1 receptor on NK...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $887,239 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate epitope switching in HIV-1 antibody responses and optimize vaccine design strategies that redirect antibody specificity toward broadly neutralizing targets. The research addresses a major barrier to HIV-1 vaccine development: the immunodominance of non-neutralizing...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $793,623 on August 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered natural killer cells for HIV reservoir targeting. The project, titled "Engineering NK Cells for Effective HIV Reservoir Targeting (ENHANCE)," aims to create chimeric antigen receptor (CAR)-expressing natural killer cells designed to target and eliminate...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $506,550 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a cross-sectional study identifying host plasma biomarkers and SomaLogic disease prognosis scores associated with cellular HIV-1 RNA expression in antiretroviral therapy–suppressed persons. The research addresses the clinical significance of persistent HIV expression after...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...